Bookmark and Share

Compound Summary for: CID 5210

sibutramine

Also known as: Meridia; Reductil; 106650-56-0; Sibutramina; Sibutraminum; Medaria; Sibutraminum [Latin]; Sibutramina [Spanish]
Molecular Formula: C17H26ClN   Molecular Weight: 279.84804   InChIKey: UNAANXDKBXWMLN-UHFFFAOYSA-N
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Biomedical Effects and Toxicity
Safety and Handling
Exposure Standards and Regulations
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _